CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-27 | Garland Jason K CFO | Grant or award | +2,540 | 8,043 | ||
| 2024-02-27 | Garland Jason K CFO | Grant or award · Stock Option (Right to Buy) | +2,523 | 2,523 | ||
| 2024-02-27 | Loeillot Olivier President and CCO | Grant or award | +2,880 | 15,786 | ||
| 2024-02-27 | Loeillot Olivier President and CCO | Grant or award · Stock Option (Right to Buy) | +2,860 | 2,860 | ||
| 2024-02-27 | DAWES KAREN A Director | Option exercise | +4,626 | $42.07 | $195K | 88,367 |
| 2024-02-27 | DAWES KAREN A Director | Sale | −1,000 | $193.35 | $193K | 87,367 |
| 2024-02-27 | DAWES KAREN A Director | Option exercise · Stock Option (Right to Buy) | +4,626 | 0 | ||
| 2024-02-23 | Bylund James Chief Operating Officer | Option exercise | +940 | $94.33 | $89K | 18,508 |
| 2024-02-23 | Bylund James Chief Operating Officer | Sale | −4,373 | $198.08 | $866K | 14,135 |
| 2024-02-23 | Bylund James Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | +940 | 4,000 | ||
| 2023-11-14 | Hunt Anthony Chief Executive Officer | Gift | −1,000 | 194,307 | ||
| 2023-11-10 | Gebski Christine See Remarks | Sale | −3,788 | $147.13 | $557K | 28,787 |
| 2023-10-02 | Loeillot Olivier President and CCO | Grant or award | +12,906 | 12,906 | ||
| 2023-10-02 | Loeillot Olivier President and CCO | Grant or award · Stock Option (Right to Buy) | +24,236 | 24,236 | ||
| 2023-09-25 | Garland Jason K CFO | Grant or award | +5,503 | 5,503 | ||
| 2023-09-25 | Garland Jason K CFO | Grant or award · Stock Option (Right to Buy) | +10,524 | 10,524 | ||
| 2023-08-29 | DAWES KAREN A Director | Option exercise | +7,392 | $18.12 | $134K | 84,591 |
| 2023-08-29 | DAWES KAREN A Director | Sale | −850 | $171.38 | $146K | 83,741 |
| 2023-08-29 | DAWES KAREN A Director | Option exercise · Stock Option (Right to Buy) | +7,392 | 0 | ||
| 2023-05-18 | Madaus Martin D Director | Grant or award | +686 | 2,297 |
Page 14 of 23 · 455 trades